| Zacks Company Profile for Arrowhead Pharmaceuticals, Inc. (ARWR : NSDQ) |
|
|
| |
| • Company Description |
| Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Number of Employees: 609 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $18.86 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,449,524 shares |
| Shares Outstanding: 138.10 (millions) |
| Market Capitalization: $2,604.57 (millions) |
| Beta: 0.93 |
| 52 Week High: $30.41 |
| 52 Week Low: $9.57 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
16.28% |
11.92% |
| 12 Week |
67.79% |
41.14% |
| Year To Date |
0.32% |
-6.05% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Christopher Anzalone - Chief Executive Officer; President and Director
Douglass Given - Chairman
Kenneth A. Myszkowski - Chief Financial Officer
Mauro Ferrari - Director
Michael S. Perry - Director
|
|
Peer Information
Arrowhead Pharmaceuticals, Inc. (CORR.)
Arrowhead Pharmaceuticals, Inc. (RSPI)
Arrowhead Pharmaceuticals, Inc. (CGXP)
Arrowhead Pharmaceuticals, Inc. (BGEN)
Arrowhead Pharmaceuticals, Inc. (GTBP)
Arrowhead Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04280A100
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 138.10
Most Recent Split Date: 11.00 (0.10:1)
Beta: 0.93
Market Capitalization: $2,604.57 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.10 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.10 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 11.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 8.66% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
